Dr Eroglu talks to ecancer at ASCO 2025 about data she presented from the SWOG S2000 phase II trial.

This is the first randomised study in patients with symptomatic BRAF V600-mutant melanoma brain metastases (MBM) comparing the efficacy of a triplet regimen (encorafenib, binimetinib, and nivolumab) against the standard ipilimumab plus nivolumab.

The study demonstrated an improvement in 6-month progression-free survival (PFS) with the triplet (50%) versus the doublet (29%), with a hazard ratio of 0.51 (p=0.07, one-sided).

Median PFS was extended to 6.2 months with the triplet compared to 1.4 months with ipi/nivo.

Response rates and toxicity profiles favored the triplet as a promising front-line option in this challenging patient population.